Effects of PYY3-36 and GLP-1 on energy intake, energy expenditure and appetite in overweight men
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Effects of PYY3-36 and GLP-1 on energy intake, energy expenditure and appetite in overweight men. / Schmidt, Julie Berg; Gregersen, Nikolaj Ture; Pedersen, Sue D; Arentoft, Johanne L; Ritz, Christian; Schwartz, Thue W.; Holst, Jens Juul; Astrup, Arne; Sjödin, Anders Mikael.
In: American Journal of Physiology: Endocrinology and Metabolism, Vol. 306, No. 11, 2014, p. E1248-E1256.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Effects of PYY3-36 and GLP-1 on energy intake, energy expenditure and appetite in overweight men
AU - Schmidt, Julie Berg
AU - Gregersen, Nikolaj Ture
AU - Pedersen, Sue D
AU - Arentoft, Johanne L
AU - Ritz, Christian
AU - Schwartz, Thue W.
AU - Holst, Jens Juul
AU - Astrup, Arne
AU - Sjödin, Anders Mikael
N1 - CURIS 2014 NEXS 112
PY - 2014
Y1 - 2014
N2 - Aim: To examine the effects of GLP-1 and PYY3-36, separately and in combination, on energy intake, energy expenditure, appetite sensations, glucose and fat metabolism, ghrelin and vital signs in healthy overweight men. Methods: 25 healthy, male subjects participated in this randomized, double-blinded, placebo-controlled 4-arm crossover study (BMI:29±3 kg/m2, age:33±9 years). On separate days they received a 150 min intravenous infusion of either a) 0.8pmol/kg/min PYY3-36, b) 1.0 pmol/kg/min GLP-1, c) a+b, or d) placebo. Ad libitum energy intake was assessed during the final 30 min. Measurements of appetite sensations, energy expenditure and fat oxidation, vital signs and blood variables were collected throughout the infusion period. Results: No effect on energy intake was found after monoinfusions of PYY3-36 (-4.2±4.8%, P=0.8) or GLP-1 (-3.0±4.5%, P=0.9). However, the co-infusion reduced energy intake compared to placebo (-30.4±6.5%, P<0.0001) and more than the sum of the monoinfusions (P<0.001), demonstrating a synergistic effect. Co-infusion slightly increased sensation of nausea (P<0.05), but this effect could not explain the effect on energy intake. A decrease in plasma ghrelin was found after all treatments compared to placebo (all P<0.05); however, infusions of GLP-1+PYY3-36 resulted in an additional decrease compared to the monoinfusions (both P<0.01).Conclusion: Co-infusion of GLP-1 and PYY3-36 exerted a synergistic effect on energy intake. The satiating effect of the meal was enhanced by GLP-1 and PYY3-36 in combination compared to placebo. Co-infusion was accompanied by slightly increased nausea and a decrease in plasma ghrelin, but neither of thesefactors could explain the reduction in energy intake.
AB - Aim: To examine the effects of GLP-1 and PYY3-36, separately and in combination, on energy intake, energy expenditure, appetite sensations, glucose and fat metabolism, ghrelin and vital signs in healthy overweight men. Methods: 25 healthy, male subjects participated in this randomized, double-blinded, placebo-controlled 4-arm crossover study (BMI:29±3 kg/m2, age:33±9 years). On separate days they received a 150 min intravenous infusion of either a) 0.8pmol/kg/min PYY3-36, b) 1.0 pmol/kg/min GLP-1, c) a+b, or d) placebo. Ad libitum energy intake was assessed during the final 30 min. Measurements of appetite sensations, energy expenditure and fat oxidation, vital signs and blood variables were collected throughout the infusion period. Results: No effect on energy intake was found after monoinfusions of PYY3-36 (-4.2±4.8%, P=0.8) or GLP-1 (-3.0±4.5%, P=0.9). However, the co-infusion reduced energy intake compared to placebo (-30.4±6.5%, P<0.0001) and more than the sum of the monoinfusions (P<0.001), demonstrating a synergistic effect. Co-infusion slightly increased sensation of nausea (P<0.05), but this effect could not explain the effect on energy intake. A decrease in plasma ghrelin was found after all treatments compared to placebo (all P<0.05); however, infusions of GLP-1+PYY3-36 resulted in an additional decrease compared to the monoinfusions (both P<0.01).Conclusion: Co-infusion of GLP-1 and PYY3-36 exerted a synergistic effect on energy intake. The satiating effect of the meal was enhanced by GLP-1 and PYY3-36 in combination compared to placebo. Co-infusion was accompanied by slightly increased nausea and a decrease in plasma ghrelin, but neither of thesefactors could explain the reduction in energy intake.
U2 - 10.1152/ajpendo.00569.2013
DO - 10.1152/ajpendo.00569.2013
M3 - Journal article
C2 - 24735885
VL - 306
SP - E1248-E1256
JO - American Journal of Physiology - Endocrinology and Metabolism
JF - American Journal of Physiology - Endocrinology and Metabolism
SN - 0193-1849
IS - 11
ER -
ID: 107926442